Oncomatryx ha desarrollado conjugados ancicuerpo-fármaco que hacen diana en la proteínas localizadas en el estroma del tumor. Una nueva vía para el tratamiento del cáncer no dirigido contra las células epiteliales del tumor sino contra los fibroblastos asociados y las células endoteliales que provocan su invasividad, la supresión inmunológica y la resistencia farmacológica.
ONCOMATRYX ANTIBODY DRUG CONJUGATES
Antibody-drug conjugates are composed of a human, humanised, or chimeric recombinant antibody, covalently bound by means of synthetic linkers to highly cytotoxic drugs. The main goal of this structure is to combine the pharmacological power of small cytotoxic drugs (300 to 1000 Da), with the high specificity of monoclonal antibodies aimed at tumour-associated antigens
The antibody must show high affinity and specificity for a tumor-associated antigen with restricted expression in normal cells. The antibody must also internalised rapidly and efficiently in target cells
The cytotoxic agent must kill target cells only after cell internalization and internal release of the toxin. The agents most frequently used for ADCs are drugs that damage DNA, such as calicheamicins and duocarmycins, or drugs targeting microtubules, such as auristatins and maytansinoids
Linkers that bind the cytotoxic agent to the antibody are designed to be stable in blood for systemic use and cleavable within the target cells to release the cytotoxic agent
The antibody-drug conjugates generated by Oncomatryx comprise human IgG1 antibodies, targeting cancer-associated fibroblasts and endothelial cells, conjugated to a 780 Da cytotoxic agent that inhibits tubulin polymerization and destabilizes microtubules
Oncomatryx proprietary linkers enhance the antitumor efficacy of ADCs 1000 times more than the classical linkers they are derived from.